Incidence of Newly Detected Atrial Arrhythmias Through Implantable Devices in Patients With a History of Thromboembolic Events
To the Editor: I read the article by Ziegler et al, 1 and their results are an important addition to the literature on the high detection rate of paroxysmal atrial fibrillation (AF) in patients with cryptogenic stroke. I have some concern, however, about some of the definitions the authors used, particularly on the duration of AF. The authors cite a report from the Heart Rhythm Society (HRS) 2 about the definition of AF being Ͼ30 seconds as a justification for longer cardiac monitoring. They comment on this duration because the study by Tayal et al 3 reported AF of Ͻ30 seconds using an external monitor. However, the HRS document directly refers to a consensus statement by the American College of Cardiology, which the authors could have referenced, and which also includes the following statement: "Episodes of AF briefer than 30 s may be important in certain clinical situations involving symptomatic patients, preexcitation or in assessing the effectiveness of therapeutic interventions." 4 I would argue that a patient with a prior embolic stroke would be considered symptomatic. Given the superiority of warfarin over aspirin for AF, and the equivalent safety and effectiveness of warfarin and aspirin in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial for cryptogenic stroke, 5 the Ͻ30-second episodes may be sufficient to change management in cryptogenic strokes. The authors then use a 5-minute justification of atrial fibrillation based on results from the MOde Selection Trial (MOST) study. 6 However, a 5-minute cutoff was only used for high rate atrial arrhythmias and was not used for AF; it was not AF that was associated with the outcomes mentioned in the report by Ziegler. The authors go on to advocate for prolonged monitors that are placed subcutaneously, which are incidentally also made by Medtronic (funding source for the article and employer of several of the authors), although a trial is currently underway to evaluate the effectiveness of these devices. Further statements on the role of the funding source may have been helpful. The authors indicate that the rate of detection of AF increased to 36% using a shorter time interval, but it may have been useful to see the Kaplan-Meier curves for that time window. It could be that an externally placed device may be sufficient to detect clinically important AF within 30 days.
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